Comments to CMS on the International Pricing Index Model for Medicare Part B Drugs Recommending Consideration of the Impact of Policy Changes on Employer Plans

The National Business Group on Health submitted comments to the CMS Administrator’s advanced notice of proposed rulemaking on the International Pricing Index for Part B Drugs recommending that any changes to the Medicare policies don’t shift costs to employer plans and that changes to “buy and bill” practices do not accelerate market consolidation and vertical integration of oncology and rheumatology practices.

icon_featured_hand

December 31, 2018

The National Business Group on Health submitted comments to the CMS Administrator’s advanced notice of proposed rulemaking on the International Pricing Index for Part B Drugs recommending that any changes to the Medicare policies don’t shift costs to employer plans and that changes to “buy and bill” practices do not accelerate market consolidation and vertical integration of oncology and rheumatology practices.

Comments to CMS on the International Pricing Index Model for Medicare Part B Drugs Recommending Consideration of the Impact of Policy Changes on Employer Plans

More Topics

Articles & Guides icon_right_chevron_dark Value-Based Care icon_right_chevron_dark
More in Policy & Advocacy